Clinical trials: Irritable Bowel Syndrome - Diarrhoea
Irritable Bowel Syndrome
Effect of Probiotic Supplement in Alleviating Functional Gastrointestinal Symptoms
The purpose of this study is to analyse the effect of a probiotic supplement on functional intestinal symptoms among subjects diagnosed with irritable bowel syndrome (IBS).
- Trial name
- NCT01728610
- Testing
- Probiotic (Active high), Probiotic (Active low)
- Where
- 2 sites in Finland
- Volunteers
- 391 people, healthy volunteers welcome
- Sponsor
- Danisco
Irritable Bowel Syndrome With Diarrhea
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Irritable Bowel Syndrome with diarrhoea (IBS-D) is a functional gastrointestinal disorder characterised by chronic or recurrent abdominal pain or discomfort and diarrhoea.
- Trial name
- IRIS-4 (NCT02120027)
- Testing
- Ibodutant 10 mg
- Where
- 139 sites in United States, Czechia and 7 more
- Volunteers
- 558 people
- Sponsor
- Menarini Group
Irritable Bowel Syndrome With Diarrhea
The Efficacy of PX0612 In The Treatment Of Irritable Bowel Syndrome
IBS is a disorder of movement in the gut. People who have IBS may have diarrhea, constipation, or alternating bouts of both. IBS is not caused by injury or illness.
- Trial name
- NCT02431533
- Testing
- PX0612, Di-Calcium Phosphate
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- Pharmabiotix Inc
Irritable Bowel Syndrome, Diarrhea
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)
The purpose of this study is to evaluate how well brenipatide (LY3537031) is tolerated, what side effects may occur, and the safety and efficacy in participants with Irritable Bowel Syndrome-Diarrhea (IBS-D).
- Trial name
- RENEW-IBS-D (NCT07545759)
- Testing
- LY3537031
- Where
- 89 sites in United States, Belgium and 8 more
- Volunteers
- 531 people
- Sponsor
- Eli Lilly and Company
Irritable Bowel Syndrome With Diarrhea
Mesalamine Granules for Irritable Bowel Syndrome (IBS) With Diarrhea
The purpose of this study is to determine the daily dose of mesalamine granules that will provide adequate relief from symptoms of IBS with diarrhea.
- Trial name
- NCT01177410
- Testing
- Mesalamine Granules 750 mg, Mesalamine Granules 1500 mg
- Where
- 20 sites in United States
- Volunteers
- 148 people
- Sponsor
- Bausch Health Americas, Inc.
Irritable Bowel Syndrome With Diarrhea
Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
This is a randomized, double-blind, placebo-controlled, 2-arm parallel group study. After qualifying for the study and signing informed consent, patients will undergo a two-week observation period during which stool consistency…
- Trial name
- NCT02757105
- Testing
- BEKINDA
- Where
- 16 sites in United States
- Volunteers
- 127 people
- Sponsor
- RedHill Biopharma Limited
Irritable Bowel Syndrome (IBS)
A Phase 2, Multi-center Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
The objective of this study is to explore efficacy, safety and tolerability of ONO-2952 in female subjects with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D).
- Trial name
- RESTORE (NCT01844180)
- Testing
- ONO-2952
- Where
- 48 sites in United States
- Volunteers
- 200 people
- Sponsor
- Ono Pharma USA Inc
Irritable Bowel Syndrome
A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)
This study is designed to evaluate the efficacy and safety of camlipixant in adults with IBS-D and IBS-M. The study has two parts.
- Trial name
- BALANCE (NCT07519395)
- Testing
- Camlipixant
- Where
- 114 sites in United States
- Volunteers
- 420 people
- Sponsor
- GlaxoSmithKline
Irritable Bowel Syndrome
Exploratory Study on Dosage of Qizhi Weitong Granules in the Treatment of Irritable Bowel Syndrome （IBS)
The purpose of this study are as follows: 1) To evaluate the efficacy and safety of Qizhi Weitong granules in the treatment of diarrhea-type irritable bowel syndrome (IBS-D);2) To explore the dosage of Qizhi Weitong Granulesin…
- Trial name
- NCT05113888
- Testing
- Qizhi weitong granules(High）, Qizhi weitong granules(Low）
- Volunteers
- 120 people
- Sponsor
- China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
Irritable Bowel Syndrome With Diarrhea
12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Irritable Bowel Syndrome with diarrhoea (IBS-D) is a functional gastrointestinal disorder characterised by chronic or recurrent abdominal pain or discomfort and diarrhoea.
- Trial name
- IRIS-3 (NCT02107196)
- Testing
- Ibodutant 10 mg
- Where
- 127 sites in United States, Bulgaria and 9 more
- Volunteers
- 535 people
- Sponsor
- Menarini Group
Diarrhea-predominant Irritable Bowel Syndrome
Special Drug Use Surveillance of Irribow in Female Patients
The purpose of the survey is to evaluate the safety and efficacy of Irribow and Irribow OD Tablets in post-marketing medical practice and to examine the status of treatment compliance.
- Trial name
- NCT02612649
- Testing
- Ramosetron
- Where
- 34 sites in Japan
- Volunteers
- 793 people
- Sponsor
- Astellas Pharma Inc
Irritable Bowel Syndrome
A Study of YM060 in Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)
This study will examine the efficacy, safety and tolerability of different oral dose of YM060, 5-HT3 receptor antagonist, in patients with d-IBS.
- Trial name
- NCT00189813
- Testing
- YM060
- Where
- 45 sites in Bulgaria, Czechia and 6 more
- Volunteers
- 691 people
- Sponsor
- Astellas Pharma Inc
Irritable Bowel Syndrome
Diarrhea Predominant Irritable Bowel Syndrome in Females
Clinical Trial with TRN-002 in Women with Irritable Bowel Syndrome (IBS) The purpose of this study is to investigate the safety and effectiveness of a new investigational drug in women for the treatment of diarrhea-predominant…
- Trial name
- NCT00461526
- Testing
- crofelemer
- Where
- 43 sites in United States
- Volunteers
- 240 people
- Sponsor
- Bausch Health Americas, Inc.
Non-Constipation Irritable Bowel Syndrome
Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)
To evaluate the efficacy of a 14-day course of rifaximin given 3 times a day vs. placebo in providing adequate relief of IBS symptoms.
- Trial name
- TARGET 2 (NCT00724126)
- Testing
- Rifaximin
- Where
- 88 sites in United States
- Volunteers
- 637 people
- Sponsor
- Bausch Health Americas, Inc.
Irritable Bowel Syndrome
A Four Arm Study to Evaluate the Safety and Efficacy of 3 Different Doses of RVX-100 Versus Placebo in Subjects With Irritable Bowel Syndrome Accompanied by Diarrhea (IBS-D)
The purpose of this study is to determine if RVX-100 is safe and effective in treating acute abdominal pain in patients with irritable bowel syndrome accompanied by diarrhea.
- Trial name
- NCT01076699
- Testing
- 0.075 mg RVX-100, 0.125 mg RVX-100, 0.250 mg RVX-100
- Where
- United States
- Volunteers
- 192 people
- Sponsor
- Revogenex, Inc.
Irritable Bowel Syndrome
A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome
The objective of this study is to evaluate the safety and efficacy of LX1033 over a range of dose levels in subjects with diarrhea-predominant Irritable Bowel Syndrome (IBS).
- Trial name
- NCT01494233
- Testing
- 250 mg LX1033 tablets
- Where
- 81 sites in United States
- Volunteers
- 373 people
- Sponsor
- Lexicon Pharmaceuticals
Irritable Bowel Syndrome
A Study of 3 Doses of Dextofisopam in Females With Irritable Bowel Syndrome
The primary objectives of this study are to evaluate the clinical safety and tolerability and to assess the efficacy of 100 mg, 200 mg, and 300 mg BID dextofisopam compared with placebo in female outpatients with…
- Trial name
- NCT00486876
- Testing
- Dextofisopam
- Where
- 79 sites in United States
- Volunteers
- 324 people
- Sponsor
- Pharmos
Irritable Bowel Syndrome With Diarrhea (IBS-D)
G-PUR® for Symptomatic Treatment in Irritable Bowel Syndrome With Diarrhea
A randomized, double-blind, placebo-controlled pilot study in patients with IBS-D according to Rome IV criteria evaluating the clinical efficacy and safety of oral administration of 2g G-PUR® tid compared to placebo in a cohort…
- Trial name
- NCT04138186
- Testing
- 2.0g G-PUR®, oral administration
- Where
- Austria
- Volunteers
- 30 people
- Sponsor
- Glock Health, Science and Research GmbH
Irritable Bowel Syndrome
Efficacy, Safety and Tolerability of DNK333 (25 and 100 mg Bid) in Women With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
This study will evaluate the tolerability, safety and efficacy of DNK333 against diarrhea caused by Irritable Bowel Syndrome in women.
- Trial name
- CDNK333B2201 (NCT00699166)
- Testing
- DNK333
- Where
- 29 sites in United States
- Volunteers
- 135 people
- Sponsor
- Novartis
Irritable Colon
Safety and Efficacy Study of GR68755 (Alosetron Hydrochloride) to Treat Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS)
This study is an exploratory study aiming (i) to obtain clinical experience of GR68755 in Japanese subjects with severe d-IBS to explore the feasibility of the next phase study and (ii) to obtain reference data for endpoints and…
- Trial name
- NCT01855711
- Testing
- GR68755 (Alosetron hydrochloride) 1 mg tablet
- Volunteers
- 32 people
- Sponsor
- GlaxoSmithKline